| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Thursday, June 18, 2020 1:39:48 PM
HK...
This is probably the most important determinate of why Du was so wrong..In 2012 when ANCHOR was completed..Virtully everyone in the lipology field held tht trig lowering ALWAYS resulted in the LDL-C levels increasing..Here to fore Trigs had been considered a risk factor for CVD events.
http://epadruginitiative.com/press/fda-puts-patients-at-risk
FDA convened an Adcom which met on Oct 13 1013..The independent panel voted on the now famous Mary Parks question..The question asked was considering the ANCHOR trial results (in light of three other trig lowering trials [Thrive, ACCORD, and AIM-HIGH]..none of which showed convincing evidence that trig lowering lowered CVD event risk) were they the panelist confident Vascepa in the suggested dose lower CVD event. The panel said no..The ANCHOR trial was not designed or powered to answer whether the drug would lower events or save lives inn those with CVD..The FDA continued in a full sweep to declare they no longer considered elevated trigs a risk factor..A position held by the AHA the ADA and the NIH..They followed shortly by reneging on the SPA they had granted Amarin..On the flimsy basis that new scientific evidence indicated EPA's ability to lower CVD event risk was unlikely..Central to FDA's turn about was that trig lowering did indeed raise LDL-C and FDA held that only LDL-C was a legit bio marker for CVD event risk..
Such were the events leading to the R-I CVOT..
It is inappropriate to consider points of view in clinical situations such as the therapeutic benefits of N-3s or "Fish Oil." By Picking out one study which supports ones point of view, where there are literally hundreds of other trials, studies or paper that do not agree. This is the very worst kind of kind of Cherry picking..And is "Fake Science" or "Judge Du Science"..That does not in anyway indicate the overall opinion of the Medical field..The truth is there was no consensuses.At the time of MORI. MORI was not a KOL..The issues were controversial and still were until a short time ago..Nothing that MORI said or did had any effect in the time and place where he said or did it..
The general view (the most agreed on) at that time would have been high Trigs are a risk factor for CVD but lowering trigs raised LDL-C and this was confirmed (expected) by the Friedwald Equation and the clinical specialists who treated Atherosclerosis. And the benefits of trig lowering were not great enough to defray the risks of raising the LDL-C..
":>) JL
This is probably the most important determinate of why Du was so wrong..In 2012 when ANCHOR was completed..Virtully everyone in the lipology field held tht trig lowering ALWAYS resulted in the LDL-C levels increasing..Here to fore Trigs had been considered a risk factor for CVD events.
http://epadruginitiative.com/press/fda-puts-patients-at-risk
FDA convened an Adcom which met on Oct 13 1013..The independent panel voted on the now famous Mary Parks question..The question asked was considering the ANCHOR trial results (in light of three other trig lowering trials [Thrive, ACCORD, and AIM-HIGH]..none of which showed convincing evidence that trig lowering lowered CVD event risk) were they the panelist confident Vascepa in the suggested dose lower CVD event. The panel said no..The ANCHOR trial was not designed or powered to answer whether the drug would lower events or save lives inn those with CVD..The FDA continued in a full sweep to declare they no longer considered elevated trigs a risk factor..A position held by the AHA the ADA and the NIH..They followed shortly by reneging on the SPA they had granted Amarin..On the flimsy basis that new scientific evidence indicated EPA's ability to lower CVD event risk was unlikely..Central to FDA's turn about was that trig lowering did indeed raise LDL-C and FDA held that only LDL-C was a legit bio marker for CVD event risk..
Such were the events leading to the R-I CVOT..
It is inappropriate to consider points of view in clinical situations such as the therapeutic benefits of N-3s or "Fish Oil." By Picking out one study which supports ones point of view, where there are literally hundreds of other trials, studies or paper that do not agree. This is the very worst kind of kind of Cherry picking..And is "Fake Science" or "Judge Du Science"..That does not in anyway indicate the overall opinion of the Medical field..The truth is there was no consensuses.At the time of MORI. MORI was not a KOL..The issues were controversial and still were until a short time ago..Nothing that MORI said or did had any effect in the time and place where he said or did it..
The general view (the most agreed on) at that time would have been high Trigs are a risk factor for CVD but lowering trigs raised LDL-C and this was confirmed (expected) by the Friedwald Equation and the clinical specialists who treated Atherosclerosis. And the benefits of trig lowering were not great enough to defray the risks of raising the LDL-C..
":>) JL
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
